Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT ID: NCT06073821

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

652 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-11

Study Completion Date

2032-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, weight loss and fever. They have shorter life expectancy compared to healthy people. There is an urgent need for new treatment to prolong life and control disease-related symptoms.

In this study, participants with CLL without prior treatment will receive either venetoclax plus obinutuzumab combination treatment that is considered a standard first line treatment or receive sonrotoclax plus zanubrutinib. It is hypothesized that sonrotoclax plus zanubrutinib may be better than venetoclax plus obinutuzumab in treating CLL.

The main purpose of this study is to compare the duration the participants live without the CLL getting worse between participants who received sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab. Approximately 652 participants will be included in this study around the world. Participants will have equal chance to be allocated to receive either of the treatment combinations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CLL

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

CLL Chronic Lymphocytic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sonrotoclax Plus Zanubrutinib

Participants will receive from start of Cycle 1 a standard dose of zanubrutinib once or twice daily orally and in combination with sonrotoclax starting from Cycle 4 onwards at increasing doses until target dose is reached and continuing until end of Cycle 15 (each cycle is 28 days)

Group Type EXPERIMENTAL

Sonrotoclax

Intervention Type DRUG

Administered orally

Zanubrutinib

Intervention Type DRUG

Administered orally

Venetoclax Plus Obinutuzumab

Participants will receive obinutuzumab 100mg intravenously on Day 1 Cycle 1, followed by 900 mg on Day 2 Cycle 1 (or alternatively receive 1000 mg intravenously on Day 1), followed by 1000 mg on Days 8 and 15 of Cycle 1 and thereafter on Day 1 of Cycles 2 through 6 (each cycle is 28 days) in combination with venetoclax at increasing doses until target dose is reached from Day 22 Cycle 1 until end of Cycle 12 (each cycles is 28 days)

Group Type ACTIVE_COMPARATOR

Venetoclax

Intervention Type DRUG

Administered orally

Obinutuzumab

Intervention Type DRUG

Administered intravenously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sonrotoclax

Administered orally

Intervention Type DRUG

Zanubrutinib

Administered orally

Intervention Type DRUG

Venetoclax

Administered orally

Intervention Type DRUG

Obinutuzumab

Administered intravenously

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BGB-11417 BGB-3111

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
* Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
* Measurable disease by Computer Tomography/Magnetic Resonance Imaging
* Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin \< 3.0 x ULN
* Adequate renal function as defined as creatinine clearance ≥ 50 milliliters per minute

Exclusion Criteria

* Previous systemic treatment for CLL
* Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
* Known central nervous system involvement
* History of confirmed progressive multifocal leukoencephalopathy (PML)
* Uncontrolled hypertension

Note: Other protocol defined criteria may apply
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BeOne Medicines

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alaska Oncology and Hematology, Llc

Anchorage, Alaska, United States

Site Status

City of Hope National Medical Center

Duarte, California, United States

Site Status

University of California San Diego (Ucsd) Moores Cancer Center

La Jolla, California, United States

Site Status

Valkyrie Clinical Trials

Los Angeles, California, United States

Site Status

UCLA Department of Medicine Hematologyoncology

Los Angeles, California, United States

Site Status

Chao Family Comprehensive Cancer Center

Orange, California, United States

Site Status

Stanford Medicine

Palo Alto, California, United States

Site Status

University of Colorado Cancer Center

Aurora, Colorado, United States

Site Status

Medstar Georgetown University Hospital

Washington D.C., District of Columbia, United States

Site Status

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States

Site Status

Moffitt Cancer Center

Tampa, Florida, United States

Site Status

Southeastern Regional Medical Center

Newnan, Georgia, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

Illinois Cancercare, Pc

Peoria, Illinois, United States

Site Status

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

Mission Cancer and Blood

Waukee, Iowa, United States

Site Status

The University of Kansas Cancer Center

Westwood, Kansas, United States

Site Status

Norton Cancer Institute Pavilion

Louisville, Kentucky, United States

Site Status

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

John Theurer Cancer Center Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Clinical Research Alliance, Inc

Westbury, New York, United States

Site Status

University of North Carolina At Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

Atrium Health Levine Cancer Institute (Lci)

Charlotte, North Carolina, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

The James Cancer Hospital and Solove Research Institute At Ohio State University

Columbus, Ohio, United States

Site Status

Oncology Associates of Oregon Willamette Valley Cancer Center

Eugene, Oregon, United States

Site Status

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Site Status

Scri Tennessee Oncology Chattanooga

Chattanooga, Tennessee, United States

Site Status

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Site Status

Virginia Cancer Institute

Richmond, Virginia, United States

Site Status

Vcu Health Systemmassey Comprehensive Cancer Center

Richmond, Virginia, United States

Site Status

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Site Status

Gunderson Health System

La Crosse, Wisconsin, United States

Site Status

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Concord Repatriation General Hospital

Concord, New South Wales, Australia

Site Status

Genesiscare North Shore

St Leonards, New South Wales, Australia

Site Status

Pindara Private Hospital

Benowa, Queensland, Australia

Site Status

Sunshine Coast Hospital and Health Service

Birtinya, Queensland, Australia

Site Status

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Site Status

Flinders Medical Centre

Bedford PK, South Australia, Australia

Site Status

Monash Health

Clayton, Victoria, Australia

Site Status

St Vincents Hospital Melbourne

Fitzroy, Victoria, Australia

Site Status

Austin Health

Heidelberg, Victoria, Australia

Site Status

Cabrini Hospital Malvern

Malvern East, Victoria, Australia

Site Status

The Alfred Hospital

Melbourne, Victoria, Australia

Site Status

Hollywood Private Hospital

Nedlands, Western Australia, Australia

Site Status

Medizinische Universitatsklinik Innsbruck

Innsbruck, , Austria

Site Status

Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg

Salzburg, , Austria

Site Status

Hanusch Krankenhaus

Vienna, , Austria

Site Status

Unesp Faculdade de Medicina Da Universidade Estadual Paulista Campus Botucatu

Botucatu, , Brazil

Site Status

Hospital Erasto Gaertner

Curitiba, , Brazil

Site Status

Centro Gaucho Integrado de Oncologia Hospital Mae de Deus

Porto Alegre, , Brazil

Site Status

Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp

Ribeirão Preto, , Brazil

Site Status

Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular

São Paulo, , Brazil

Site Status

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

São Paulo, , Brazil

Site Status

Arthur Je Child Comprehensive Cancer Centre

Calgary, Alberta, Canada

Site Status

Cross Cancer Institute

Edmonton, Alberta, Canada

Site Status

British Columbia Cancer Agency the Vancouver Centre

Vancouver, British Columbia, Canada

Site Status

Cancercare Manitoba

Winnipeg, Manitoba, Canada

Site Status

Lakeridge Health

Oshawa, Ontario, Canada

Site Status

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Site Status

Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre

Greenfield Park, Quebec, Canada

Site Status

Centre Hospitalier de Luniversite de Montreal (Chum)

Montreal, Quebec, Canada

Site Status

Unite de Recherche Clinique Du Cisss Des Laurentides

SaintJerome, Quebec, Canada

Site Status

Ciusss de Lestrie Chus

Sherbrooke, Quebec, Canada

Site Status

Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)

Québec, , Canada

Site Status

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Site Status

Peking University Third Hospital

Beijing, Beijing Municipality, China

Site Status

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China

Site Status

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Site Status

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Site Status

Jieyang Peoples Hospital (Jieyang Affiliated Hospital, Sun Yat Sen University )

Jieyang, Guangdong, China

Site Status

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

Site Status

Nanyang Central Hospital

Nanyang, Henan, China

Site Status

Henan Cancer Hospital

Zhengzhou, Henan, China

Site Status

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status

Yichang Central Peoples Hospitaljiangnan Branch

Yichang, Hubei, China

Site Status

The First Peoples Hospital of Changzhou

Changzhou, Jiangsu, China

Site Status

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Site Status

Affiliated Hospital of Nantong University

Nantong, Jiangsu, China

Site Status

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Site Status

The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Site Status

The First Hospital of China Medical University

Shenyang, Liaoning, China

Site Status

The Second Affiliated Hospital of Xian Jiaotong University

Xi'an, Shaanxi, China

Site Status

Shandong Provincial Hospital

Jinan, Shandong, China

Site Status

Jining No Peoples Hospital West Branch

Jining, Shandong, China

Site Status

Yantai Yuhuangding Hospital

Yantai, Shandong, China

Site Status

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Site Status

Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

Chengdu, Sichuan, China

Site Status

Institute of Hematology and Hospital of Blood Disease

Tianjin, Tianjin Municipality, China

Site Status

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Site Status

Fakultni Nemocnice Brno

Brno, , Czechia

Site Status

Fakultni Nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

Fakultni Nemocnice Olomouc

Olomouc, , Czechia

Site Status

Fakultni Nemocnice Ostrava

Ostrava, , Czechia

Site Status

Fakultni Nemocnice Plzen

PLZE, , Czechia

Site Status

Vseobecna Fakultni Nemocnice V Praze

Prague, , Czechia

Site Status

Centre de Lutte Contre Le Cancer Institut Bergonie

Bordeaux, , France

Site Status

Chu Clermont Ferrand Therapie Cellulaire and Hematolo

Clermontferrand, , France

Site Status

Clinique Louis Pasteur

Esseylesnancy, , France

Site Status

Centre Hospitalier Le Mans

Le Mans, , France

Site Status

Chu Lille

Lille, , France

Site Status

Centre Leon Berard

Lyon, , France

Site Status

Centre Hospitalier Universitaire Nantes Hotel Dieu

Nantes, , France

Site Status

Hopital Prive Du Confluent

Nantes, , France

Site Status

Hopital de La Pitie Salpetriere

Paris, , France

Site Status

Chu Rennes

Rennes Cedes, , France

Site Status

Centre Henri Becquerel

Rouen, , France

Site Status

Chu Tours Hopital Bretonneau

Tours, , France

Site Status

Chu Nancy Hopital Brabois

VandoeuvrelesNancy, , France

Site Status

Praxis Am Volkspark

Berlin, , Germany

Site Status

Centrum Fur Haematologie Und Onkologie Bethanien

Frankfurt am Main, , Germany

Site Status

Universitaetsklinikum Schleswig Holstein Campus Luebeck

Lübeck, , Germany

Site Status

Assuta Ashdod Medical Center

Ashdod, , Israel

Site Status

Carmel Medical Center

Haifa, , Israel

Site Status

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status

Hadassah University Hospital Ein Kerem

Jerusalem, , Israel

Site Status

Assuta Medical Center

Tel Aviv, , Israel

Site Status

Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi

Bologna, , Italy

Site Status

Azienda Ospedaliero Universitaria Di Ferrara

Ferrara, , Italy

Site Status

Istituto Europeo Di Oncologia

Milan, , Italy

Site Status

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Milan, , Italy

Site Status

Aou Maggiore Della Carita

Novara, , Italy

Site Status

Azienda Ospedaliera Di Padova

Padua, , Italy

Site Status

Ospedale Santa Maria Della Misericordia

Perugia, , Italy

Site Status

Aichi Cancer Center Hospital Clinical Oncology

Nagoya, Aichi-ken, Japan

Site Status

Chiba Cancer Center

Chiba, Chiba, Japan

Site Status

Nho Shikoku Cancer Center

Matsuyama, Ehime, Japan

Site Status

Aiiku Hospital

Sapporo, Hokkaido, Japan

Site Status

Hyogo Prefectural Amagasaki General Medical Center

AmagasakiCity, Hyōgo, Japan

Site Status

Kagoshima University Hospital

Kagoshima, Kagoshima-ken, Japan

Site Status

Tokai University Hospital

Iseharashi, Kanagawa, Japan

Site Status

Tohoku University Hospital

Sendai, Miyagi, Japan

Site Status

Niigata University Medical and Dental Hospital

Niigata, Niigata, Japan

Site Status

Kurashiki Central Hospital

Kurashikishi, Okayama-ken, Japan

Site Status

Kansai Medical University Hospital

Hirakata, Osaka, Japan

Site Status

Kindai University Hospital

Sayama, Osaka, Japan

Site Status

National Cancer Center Hospital

ChuoKu, Tokyo, Japan

Site Status

Yamagata University Hospital

Yamagata, Yamagata, Japan

Site Status

Aomori Prefectural Central Hospital

Aomori, , Japan

Site Status

Kumamoto University Hospital

Kumamoto, , Japan

Site Status

National Hospital Organization Okayama Medical Center

Okayama, , Japan

Site Status

Osaka Metropolitan University Hospital

Osaka, , Japan

Site Status

Yokohama Municipal Citizens Hospital

Yokohama, , Japan

Site Status

Noordwest Ziekenhuisgroep

Alkmaar, , Netherlands

Site Status

Flevoziekenhuis

Almere Stad, , Netherlands

Site Status

Meander Medisch Centrum

Amersfoort, , Netherlands

Site Status

Amsterdam Umc Vu Mc

Amsterdam, , Netherlands

Site Status

Albert Schweitzer Ziekenhuis

Dordrecht, , Netherlands

Site Status

Martini Ziekenhuis

Groningen, , Netherlands

Site Status

Maasstad Hospital

Rotterdam, , Netherlands

Site Status

Ikazia Ziekenhuis

Rotterdam, , Netherlands

Site Status

Franciscus Gasthuis and Vlietland

Schiedam, , Netherlands

Site Status

Hagaziekenhuis

Sgravenhage, , Netherlands

Site Status

North Shore Hospital

Auckland, , New Zealand

Site Status

Auckland City Hospital

Auckland, , New Zealand

Site Status

Health New Zealand Canterbury

Christchurch, , New Zealand

Site Status

Dunedin Hospital

Dunedin, , New Zealand

Site Status

Tauranga Hospital

Tauranga, , New Zealand

Site Status

Wellington Regional Hospital (Ccdhb)

Wellington, , New Zealand

Site Status

Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi

Lodz, , Poland

Site Status

Uniwersytecki Szpital Kliniczny Nr W Lublinie

Lublin, , Poland

Site Status

Uniwersytecki Szpital Kliniczny W Poznaniu

Poznan, , Poland

Site Status

Centralny Szpital Kliniczny Uck Wum

Warsaw, , Poland

Site Status

Instytut Hematologii I Transfuzjologii

Warsaw, , Poland

Site Status

Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu

Wroclaw, , Poland

Site Status

Auxilio Mutuo Cancer Center

San Juan, , Puerto Rico

Site Status

Seoul National University Bundang Hospital

BundangGu SeongnamSi, Gyeonggi-do, South Korea

Site Status

National Cancer Center (Korea)

IlsandongGu GoyangSi, Gyeonggi-do, South Korea

Site Status

The Catholic University of Korea, Seoul St Marys Hospital

SeochoGu, Seoul Teugbyeolsi, South Korea

Site Status

Severance Hospital Yonsei University Health System

SeodaemunGu, Seoul Teugbyeolsi, South Korea

Site Status

Seoul National University Hospital

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Asan Medical Center

SongpaGu, Seoul Teugbyeolsi, South Korea

Site Status

Hospital Universitario de Burgos

Burgos, , Spain

Site Status

Institut Catala Doncologia Hospital Duran I Reynals

L'Hospitalet de Llobregat, , Spain

Site Status

Hospital Universitario de Gran Canaria Dr Negrin

Las Palmas de Gran Canaria, , Spain

Site Status

Md Anderson Cancer Center Madrid Spain

Madrid, , Spain

Site Status

Hospital Universitario Ramon Y Cajal

Madrid, , Spain

Site Status

Hospital Universitario de Octubre

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital La Candelaria

Santa Cruz de Tenerife, , Spain

Site Status

Karolinska Universitetssjukhuset Solna

Stockholm, , Sweden

Site Status

Ankara University Medical Faculty

Ankara, , Turkey (Türkiye)

Site Status

Gazi University

Ankara, , Turkey (Türkiye)

Site Status

Erciyes University School of Medicine

Kayseri, , Turkey (Türkiye)

Site Status

Kocaeli Universitesi Tip Fakultesi

Kocaeli, , Turkey (Türkiye)

Site Status

University Hospitals Dorset Royal Bournemouth Hospital

Bournemouth, , United Kingdom

Site Status

Kent and Canterbury Hospital

Canterbury, , United Kingdom

Site Status

Churchill Hospital Oxford University Hospital Nhs Trust

Headington, , United Kingdom

Site Status

St Jamess University Hospital

Leeds, , United Kingdom

Site Status

The Clatterbridge Cancer Centre Liverpool

Liverpool, , United Kingdom

Site Status

University College Hospital

London, , United Kingdom

Site Status

Kings College

London, , United Kingdom

Site Status

Norfolk and Norwich University Hospitals Nhs Foundation Trust

Norwich, , United Kingdom

Site Status

Southampton General Hospital

Southampton, , United Kingdom

Site Status

Royal Marsden Nhs Foundation Royal Marsden Hospital

Sutton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia United States Australia Austria Brazil Canada China Czechia France Germany Israel Italy Japan Netherlands New Zealand Poland Puerto Rico South Korea Spain Sweden Turkey (Türkiye) United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTR20241195

Identifier Type: OTHER

Identifier Source: secondary_id

BGB-11417-301

Identifier Type: -

Identifier Source: org_study_id